X

Health & Biotech

Health: Funding from ScoMo sends PainChek rocketing 91pc to seven-month high

News the Morrison Government will invest $5 million to sponsor a clinical trial of PainChek's (ASX:PCK) pain recognition app in aged…

The Pot Seat: Emerald’s Stewart Washer says they’re listing this year

Emerald Clinics has been promising an IPO for about a year but has seen the writing on the wall: after…

Rhinomed breathing easy thanks to strong March quarter, shares rise 26pc

Breathing medtech company Rhinomed (ASX:RNO) had its best day on the ASX in about six months on Monday, hitting highs of 24c…

How the biotech community is fighting back against superbugs

It's not a bird, nor a plane, it's superbugs. And it will take something more than Superman to fight them…

Dr Boreham’s Crucible: Sienna’s first acquisition opens up the field of play

Shortly after listing in November 2017, the bladder cancer diagnostics house outlined a plan to acquire or in-licence complementary technologies…

Health: Elixinol pivots to pet pot treats, nabs 25pc stake in US hemp manufacturer

Australia's most successful pot stock Elixinol (ASX: EXL) is on the acquisition path. The hemp-growing company announced this morning that…

ResApp trial sends shares up 36pc as rollercoaster ride continues

Shares in ResApp (ASX:RAP) have jumped 36 per cent this morning to six-month highs after it announced positive results from an…

Dr Boreham’s Crucible: Are China and the US finally waking up to Compumedics?

Perseverance is the byword at the Melbourne based Compumedics (ASX: CMP), which has become a global market leader in sleep…

Biotech bosses vs investors: are you misunderstanding or are they bad at explaining?

There has been a bit of confusion between biotech bosses and their shareholders this year. In November Mesoblast (ASX:MSB) boss…

Creso doubles down on LatAm with Brazil cannabis import licence

Special Report: Creso Pharma has won a Brazil import licence for its cannaQIX®50 medical cannabis. South America is the next…